Form 4: Sangamo Therapeutics Director Meyers Acquires Shares and Options

Director James R. Meyers acquired 25,000 shares of common stock and options to purchase 50,000 shares of Sangamo Therapeutics stock on June 4, 2024.

Summary

• On June 4, 2024, James R. Meyers, a director of Sangamo Therapeutics, acquired 25,000 shares of common stock.
• These shares were obtained through the settlement of a restricted stock unit (RSU) grant.
• The RSU grant will fully vest on the earlier of June 4, 2025, or the day prior to the 2025 annual meeting of stockholders, contingent upon continuous service.
• Meyers also acquired options to purchase 50,000 shares of common stock at an exercise price of $0.5676.
• The options are immediately exercisable, but unvested shares purchased under the option are subject to repurchase rights by the issuer upon cessation of continuous service.
• The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to continuous service.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of insider transactions. The acquisition of shares and options could be seen as a positive sign, but it's not a strong indicator of future performance.

Positives

• The director's acquisition of shares and options may signal confidence in the company's future prospects.

Risks

• The vesting of the shares and options is contingent upon the director's continuous service, creating a potential risk if service is terminated.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting schedules of the RSUs and stock options suggest a continued involvement of the director with the company.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings for signals about management's confidence in the company's prospects.

Comparison to Industry Standards

• Equity compensation is a standard practice in the biotechnology industry to align the interests of management and shareholders.
• Vesting schedules and exercise prices are typically structured to incentivize long-term performance.
• Companies like CRISPR Therapeutics and Editas Medicine also use similar equity compensation plans for their executives and directors.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment if interpreted as a sign of confidence from a director.

Key Dates